#Sustainability in #Healthcare The Time to Act is Now Sadeer Al-Kindi, MD Susan Moffatt-Bruce Saurabh S Dani, MD, MSc healio.com/news/cardiolog…

Atrial Fibrillation Burden and Clinical Outcomes in Patients with BTK Inhibitor Cardiotoxicity: nature.com/articles/s4137… Thanks Leukemia Journal for publishing this work. #CardioOnc #CLL #BTK #AtrialFibrillation #leukemia Alan Gambril, MD International Cardio-Oncology Society Eric H Yang, MD

GLP-1 receptor agonist use on top of SGLT2 inhibition in patients with #HFpEF, type 2 diabetes and #obesity was associated with reduced risk for adverse events vs. SGLT2 inhibition alone American College of Cardiology #Cardiotwitter Endocrine Today Nephrology News & Issues Read more👇 healio.com/news/cardiolog…

Thrilled to share our paper in JACC Journals #Advances showing the importance of #AI derived epicardial adipose tissue radiomics for CV risk assessment. A step towards maximizing the value of cardiac CT beyond Agatston scoring for #CVPrevention #yesCCT jacc.org/doi/10.1016/j.…

#SGLT2i and #GLP1 are both independently shown to benefit patients with #HFpEF #heartfailure But can #GLP1 provide incremental benefits to those already on #SGLT2i ? The answer is YES ✅️✅️✅️ For patients with #diabetes #HFpEF & #Obesity #realworlddata ➡️ Use of #GLP1

Kudos to the incredible vision, leadership, nimble operations and teamwork at JACC! An outstanding effort to rapidly deliver the latest science to our readers—what a fantastic start for the new JACC Journals team! American College of Cardiology #ESC2024

‼️3.6% of the participants randomized in the STEP-HFpEF trial had concomitant SGLT2i administration. 📚Read our paper titled “GLP-1 Receptor Agonists among Patients with Overweight or Obesity, Diabetes and HFpEF on SGLT2 Inhibitors”. Mayo Clinic Rochester Cardiology Fellows Mayo Clinic CV

Multi-Institute study in JACC Journals led by Lahey Hospital investigators shows incremental benefits of #GLP1RA in addition to #SGLT2i for those with #heartfailure #HFpEF #obesity #diabetes sciencedirect.com/science/articl…

It doesn’t matter how you slice or dice the dyslipidemia pie As shown in this paper as well as multiple prior publications, ascvd risk is directly associated with presents and burden of CAC Doesn’t matter if you have high/low LDL or HDL It’s as simple as that 👇

#HeliosB #ESCCongress #Friday #Hotline 🍩 patients with ATTR-CM, 💊 with vutrisiran led to a ⬇️ risk of death from any cause and cardiovascular events than placebo and ↔️preserved functional capacity and quality of life. Beautiful infographic European Society of Cardiology 🔗

Which #coffee & which #myocardialviability method?The most fun #ESCCongress2024 discussion by absolutely phenomenal Dr Mark Westwood Alessia Gimelli European Society of Cardiology News European Society of Cardiology Journals

How to implement #CardioOnc guidelines? Multidisciplinary Team is Key: check Joint ESMO - Eur. Oncology European Society of Cardiology session #ESCCongress2024 with Great talks by Evandro de Azambuja, MD, PhD #drValentinaGuarneri Jutta Bergler-Klein European Society of Cardiology News Teresa López Fdez

SUCCOUR-MRI randomized pts w GLS decline to cardioprotection vs no treatment and showed benefit. Honored to write the Editorial with my #Oncology colleagues Inova Schar Cancer Institute on how this informs our joint care Inova European Society of Cardiology Journals academic.oup.com/eurheartj/arti…

Join us for the Lahey Cancer Institute Walk on Saturday, September 7, 2024 in support of our patients - every step counts! Sign up today to make a difference⬇️ runsignup.com/Race/MA/Burlin…

Would love to see the threshold LDL mg/years (total plaque burden) for South Asian population for plaque rupture. Too long to wait for 5000 LDL-years! #Premature CAD Sarju Ganatra, MD, FACC Jaideep Alka Kanaya Priyanka Satish Anandita Agarwala Kulkarni, MD FACC Khurram Nasir Salim Virani Dinesh Kalra, MD Romit Bhattacharya

Saurabh S Dani, MD, MSc Sarju Ganatra, MD, FACC Jaideep Alka Kanaya Priyanka Satish Anandita Agarwala Kulkarni, MD FACC Salim Virani Dinesh Kalra, MD Romit Bhattacharya Athero very heterogeneous and complicated process and trying to simplify as an easy concept as "LDL life years" is just not good science or policy Huge differences across the LDL years spectrum where folks develop at a lower threshold and never with highest lifetime exposure.

Very proud of amazing Ginny Sun, MD from MGH IM Residents. Co-led with Kerry Reynolds from Mass General Cancer Center. Large language models with an excellent sensitivity and specificity for several key ICI associated adverse events and in 9 secs. Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

GLP-1 RA, in addition to SGLT2i, associated with a significantly lower risk of heart failure hospitalisation sciencedirect.com/science/articl…

Superb work by Lahey Cardiology stellar fellow Rushin Patel MD and fantastic collaborators led by Sarju Ganatra, MD, FACC !

Today was published the EMPACARD - PILOT Trial!!! The first prospective study using SGLT2i like prevention strategy of CTRCD!!! Thanks Vanesa Gregorietti Teresa López Fdez Diego Costa Lourdes M. Figueiras-Graillet Juan Carlos Plana Juliana Salas Joerg Herrmann iLACO International Cardio-Oncology Society Soc Esp Cardiología ACORA